Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.62 -5.1%	$0.64	$0.51 ▼ $1.80	$59.09M	0.29	657,704 shs	537,519 shs
PRLD Prelude Therapeutics	$1.04 -5.5%	$0.86	$0.61 ▼ $6.80	$58.72M	1.25	281,098 shs	87,405 shs
RPTX Repare Therapeutics	$1.45 +0.7%	$1.28	$0.89 ▼ $4.29	$62.19M	0.84	252,435 shs	76,658 shs
TTPH Tetraphase Pharmaceuticals	$2.20	$2.20	$0.56 ▼ $8.60	$15.98M	2.33	932,542 shs	282,689 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	-1.35%	-2.19%	+5.95%	-9.51%	-39.63%
PRLD Prelude Therapeutics	+1.39%	+9.51%	+24.05%	+54.90%	-72.76%
RPTX Repare Therapeutics	-2.70%	-0.69%	+5.88%	+28.57%	-62.11%
TTPH Tetraphase Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	2.4485 of 5 stars	3.5	1.0	0.0	0.0	3.3	0.8	1.3
PRLD Prelude Therapeutics	3.2471 of 5 stars	3.2	2.0	0.0	0.0	3.2	5.0	0.6
RPTX Repare Therapeutics	2.452 of 5 stars	3.3	3.0	0.0	0.0	1.6	2.5	0.6
TTPH Tetraphase Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.75	345.78% Upside
PRLD Prelude Therapeutics	2.33	Hold	$4.00	284.62% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	210.34% Upside
TTPH Tetraphase Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TTPH, ASRT, RPTX, and PRLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50
5/13/2025	ASRT Assertio	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/5/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/29/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00 ➝ $4.00
4/8/2025	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.50
3/14/2025	ASRT Assertio	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$1.75

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$119.00M	0.50	$0.55 per share	1.12	$1.46 per share	0.42
PRLD Prelude Therapeutics	$7M	8.39	N/A	N/A	$4.32 per share	0.24
RPTX Repare Therapeutics	$1.07M	57.96	N/A	N/A	$5.03 per share	0.29
TTPH Tetraphase Pharmaceuticals	$7.38M	2.17	N/A	N/A	$6.68 per share	0.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$331.94M	-$0.32	N/A	20.56	3.25	-54.46%	3.79%	1.81%	8/6/2025 (Estimated)
PRLD Prelude Therapeutics	-$121.83M	-$1.69	N/A	N/A	N/A	N/A	-66.89%	-55.59%	8/11/2025 (Estimated)
RPTX Repare Therapeutics	-$93.80M	-$3.01	N/A	N/A	N/A	-99.76%	-40.87%	-35.07%	N/A
TTPH Tetraphase Pharmaceuticals	-$70.08M	-$22.85	N/A	N/A	N/A	-798.18%	-210.86%	-121.73%	N/A

Latest TTPH, ASRT, RPTX, and PRLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	ASRT Assertio	-$0.06	-$0.14	-$0.08	-$0.14	$27.52 million	$26.49 million
5/6/2025	Q1 2025	PRLD Prelude Therapeutics	-$0.47	-$0.42	+$0.05	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
TTPH Tetraphase Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.30	2.01	1.57
PRLD Prelude Therapeutics	N/A	7.04	7.04
RPTX Repare Therapeutics	N/A	6.45	6.45
TTPH Tetraphase Pharmaceuticals	0.06	3.66	3.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
PRLD Prelude Therapeutics	79.72%
RPTX Repare Therapeutics	85.09%
TTPH Tetraphase Pharmaceuticals	42.29%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
PRLD Prelude Therapeutics	63.90%
RPTX Repare Therapeutics	11.50%
TTPH Tetraphase Pharmaceuticals	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	95.78 million	92.42 million	Optionable
PRLD Prelude Therapeutics	120	56.46 million	20.47 million	Optionable
RPTX Repare Therapeutics	180	42.89 million	33.33 million	Optionable
TTPH Tetraphase Pharmaceuticals	119	7.26 million	N/A	Optionable

TTPH, ASRT, RPTX, and PRLD Headlines

Recent News About These Companies

NAFDAC Seeks More Synergy with Indian Pharmaceutical Sector

March 12, 2023 | thisdaylive.com

Infinity Pharmaceuticals Stock (NASDAQ:INFI), Quotes and News Summary

February 26, 2023 | benzinga.com

Tetraphase Pharmaceuticals (TTPH) Stock Tanks on Weak Phase 3 Test Results

August 30, 2022 | thestreet.com

Tetraphase Executive Profits Hours Before Stock Plummets

August 20, 2022 | thestreet.com

TTPH_old Historical Data

April 4, 2022 | investing.com

10 Worst NASDAQ Biotech Stocks in the Third Quarter

January 16, 2022 | thestreet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTPH, ASRT, RPTX, and PRLD Company Descriptions

Assertio NASDAQ:ASRT

$0.62 -0.03 (-5.09%)

As of 04:00 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Prelude Therapeutics NASDAQ:PRLD

$1.04 -0.06 (-5.45%)

As of 04:00 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Repare Therapeutics NASDAQ:RPTX

$1.45 +0.01 (+0.69%)

As of 03:59 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Tetraphase Pharmaceuticals NASDAQ:TTPH

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time